These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 29219151)

  • 21. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment.
    Lind S; Olsson AG; Eriksson M; Rudling M; Eggertsen G; Angelin B
    J Intern Med; 2004 Nov; 256(5):406-12. PubMed ID: 15485476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in the care of familial hypercholesterolaemia: 2016.
    Bell DA; Watts GF
    Med J Aust; 2016 Sep; 205(5):232-6. PubMed ID: 27581271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
    Stefanutti C; Mazza F; Mesce D; Morozzi C; Di Giacomo S; Vitale M; Pergolini M
    Atheroscler Suppl; 2017 Nov; 30():86-91. PubMed ID: 29096866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease.
    Moss S; Tardo D; Doyle M; Rees D
    Cardiovasc Revasc Med; 2018 Dec; 19(8S):20-22. PubMed ID: 30017729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cascade screening for familial hypercholesterolemia: Practical consequences.
    Louter L; Defesche J; Roeters van Lennep J
    Atheroscler Suppl; 2017 Nov; 30():77-85. PubMed ID: 29096865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment.
    Maliachova O; Stabouli S
    Curr Pharm Des; 2018; 24(31):3672-3677. PubMed ID: 30317987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for familial hypercholesterolaemia.
    Bender R; Bell DA; Hooper AJ; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR
    Pathology; 2012 Feb; 44(2):122-8. PubMed ID: 22228254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modern Management of Familial Hypercholesterolemia.
    Duell PB; Jialal I
    Metab Syndr Relat Disord; 2016 Dec; 14(10):463-467. PubMed ID: 27797643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
    Lee WP; Datta BN; Ong BB; Rees A; Halcox J
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
    Pijlman AH; Huijgen R; Verhagen SN; Imholz BP; Liem AH; Kastelein JJ; Abbink EJ; Stalenhoef AF; Visseren FL
    Atherosclerosis; 2010 Mar; 209(1):189-94. PubMed ID: 19818960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia - a proof-of-concept study.
    Maurer F; Pradervand S; Guilleret I; Nanchen D; Maghraoui A; Chapatte L; Bojkowska K; Bhuiyan ZA; Jacquemont N; Harshman K; Mooser V
    Swiss Med Wkly; 2016; 146():w14326. PubMed ID: 27497240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.
    Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J
    BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document].
    Mata P; Alonso R; Ruiz A; Gonzalez-Juanatey JR; Badimón L; Díaz-Díaz JL; Muñoz MT; Muñiz O; Galve E; Irigoyen L; Fuentes-Jiménez F; Dalmau J; Pérez-Jiménez F
    Semergen; 2015; 41(1):24-33. PubMed ID: 25042971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.